These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 12781905)

  • 1. How cost-effective are new preventive strategies for cardiovascular disease?
    Probstfield JL
    Am J Cardiol; 2003 May; 91(10A):22G-27G. PubMed ID: 12781905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The ongoing telmisartan alone and in combination with ramipril global endpoint trial program.
    Unger T
    Am J Cardiol; 2003 May; 91(10A):28G-34G. PubMed ID: 12781906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials.
    Teo K; Yusuf S; Sleight P; Anderson C; Mookadam F; Ramos B; Hilbrich L; Pogue J; Schumacher H;
    Am Heart J; 2004 Jul; 148(1):52-61. PubMed ID: 15215792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis.
    Yusuf S
    Am J Cardiol; 2002 Jan; 89(2A):18A-25A; discussion 25A-26A. PubMed ID: 11835907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease.
    Verdecchia P; Sleight P; Mancia G; Fagard R; Trimarco B; Schmieder RE; Kim JH; Jennings G; Jansky P; Chen JH; Liu L; Gao P; Probstfield J; Teo K; Yusuf S;
    Circulation; 2009 Oct; 120(14):1380-9. PubMed ID: 19770395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The ONTARGET/TRANSCEND Trial Programme: baseline data.
    Sleight P
    Acta Diabetol; 2005 Apr; 42 Suppl 1():S50-6. PubMed ID: 15868120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Challenges in improving prognosis and therapy: the Ongoing Telmisartan Alone and in Combination with Ramipril Global End point Trial programme.
    Zimmermann M; Unger T
    Expert Opin Pharmacother; 2004 May; 5(5):1201-8. PubMed ID: 15155118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances in cardiovascular risk reduction: implications of ONTARGET.
    Guthrie R
    Clin Cornerstone; 2009; 9 Suppl 3():S18-26. PubMed ID: 19409352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Telmisartan for the management of patients at high cardiovascular risk.
    Ruilope LM
    Curr Med Res Opin; 2011 Aug; 27(8):1673-82. PubMed ID: 21718097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin II and trials of cardiovascular outcomes.
    Sleight P
    Am J Cardiol; 2002 Jan; 89(2A):11A-16A; discussion 16A-17A. PubMed ID: 11835905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cost implications of the use of telmisartan or ramipril in patients at high risk for vascular events: the ONTARGET study.
    Lamy A; Wang X; Gao P; Tong W; Gafni A; Dans A; Avezum A; Ferreira R; Young J; Yusuf S; Teo K;
    J Med Econ; 2011; 14(6):792-7. PubMed ID: 21981559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lessons learned from the ONTARGET and TRANSCEND trials.
    Basile J
    Curr Atheroscler Rep; 2009 Sep; 11(5):371-6. PubMed ID: 19664381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Left ventricular mass and volume with telmisartan, ramipril, or combination in patients with previous atherosclerotic events or with diabetes mellitus (from the ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial [ONTARGET]).
    Cowan BR; Young AA; Anderson C; Doughty RN; Krittayaphong R; Lonn E; Marwick TH; Reid CM; Sanderson JE; Schmieder RE; Teo K; Wadham AK; Worthley SG; Yu CM; Yusuf S; Jennings GL;
    Am J Cardiol; 2009 Dec; 104(11):1484-9. PubMed ID: 19932779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cardiac MRI substudy to ongoing telmisartan alone and in combination with ramipril global endpoint trial/telmisartan randomized assessment study in ACE-intolerant subjects with cardiovascular disease: analysis protocol and baseline characteristics.
    Cowan BR; Young AA; Anderson C; Doughty RN; Krittayaphong R; Lonn E; Marwick TH; Reid CM; Sanderson JE; Schmieder RE; Teo K; Wadham AK; Worthley SG; Yu CM; Yusuf S; Jennings GL
    Clin Res Cardiol; 2009 Jul; 98(7):421-33. PubMed ID: 19347385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies.
    Tobe SW; Clase CM; Gao P; McQueen M; Grosshennig A; Wang X; Teo KK; Yusuf S; Mann JF;
    Circulation; 2011 Mar; 123(10):1098-107. PubMed ID: 21357827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In a subgroup of high-risk Asians, telmisartan was non-inferior to ramipril and better tolerated in the prevention of cardiovascular events.
    Dans AL; Teo K; Gao P; Chen JH; Jae-Hyung K; Yusoff K; Chaithiraphan S; Zhu J; Lisheng L; Yusuf S;
    PLoS One; 2010 Dec; 5(12):e13694. PubMed ID: 21200437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are ACE-inhibitors or ARB's still needed for cardiovascular prevention in high risk patients? Insights from profess and transcend.
    Van Mieghem W; Billiouw JM; Brohet C; Dupont AG; Gazagnes MD; Heller F; Krzesinski JM; Missault L; Persu A; Piérard L; Rottiers R; Vanhooren G; Vervaet P; Herman AG
    Acta Clin Belg; 2010; 65(2):107-14. PubMed ID: 20491360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Telmisartan prevents cardiovascular events in a broad group of at-risk patients.
    Baumhäkel M; Böhm M
    Expert Opin Pharmacother; 2009 Dec; 10(18):3113-7. PubMed ID: 19925045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rationale and design of the cardiac magnetic resonance imaging substudy of The ONTARGET Trial Programme.
    Anderson C
    J Int Med Res; 2005; 33 Suppl 1():50A-57A. PubMed ID: 16222900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erectile dysfunction predicts cardiovascular events in high-risk patients receiving telmisartan, ramipril, or both: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET/TRANSCEND) Trials.
    Böhm M; Baumhäkel M; Teo K; Sleight P; Probstfield J; Gao P; Mann JF; Diaz R; Dagenais GR; Jennings GL; Liu L; Jansky P; Yusuf S;
    Circulation; 2010 Mar; 121(12):1439-46. PubMed ID: 20231536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.